Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04867616 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 2
- Development phase
- 466
- Enrollment target
NCT04867616: Completed Phase 2 study, sponsored by UCB Biopharma SRL.
NCT04867616 is a Phase 2 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 466 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (250% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04867616, a Phase 2 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 466 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's Disease (AD).
Primary Outcome
The Clinical Dementia Rating (CDR) scale is a clinician-rated dementia staging system that tracks the progression of cognitive impairment in 6 categories (memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care). Each category is scored on a 5-point scale in which None=0, Questionable=0.5, Mild=1, Moderate=2, and Severe=3. The global CDR score is established by clinical scoring rules and has values of 0 (no dementia), 0.5, (questionable dementia)
Interventions
- OTHER Placebo
- BIOLOGICAL Bepranemab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 2 |
What the finished NCT04867616 record still lists
NCT04867616 is an interventional study that assigns participants to a tested intervention. The registered 466 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (250% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04867616 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04867616 about?
NCT04867616 is a clinical study titled "A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)". The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's Disease (AD).
What is the current status of trial NCT04867616?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 466 participants. The study started on 2021-06-09. Estimated completion is 2025-08-01.
What interventions are being tested in trial NCT04867616?
The interventions under investigation include: Placebo (OTHER), Bepranemab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04867616?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04867616's enrollment target sits among peer trials
466 80th of 2000 higher than 1,921 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05312879 · 466 participants · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
- NCT06917404 · 466 participants · Phase 3
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
- NCT07055165 · 466 participants · NA
Connect2Care: Prostate Cancer Education and Screenings for African American Men
- NCT07214779 · 466 participants · Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI